• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Call Text Chat Email Refer a Patient Join a Study

Search

Hide Search
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Shopping Cart
Show SearchSearch
  • English
    • Español (Spanish)
  • About
    • Our Work
    • Our Team
    • About OTIS
    • In Your Area
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Webinars
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Annual Meeting
    • Exhibiting Schedule
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • Donate
  • Contact
  • Show SearchSearch

Results from the Vedolizumab MotherToBaby Pregnancy Study

What the Study Found About Vedolizumab Use During Pregnancy.

Learn More

COVID-19, Flu & RSV Vaccines

Have questions about protecting yourself from COVID-19, the flu, and RSV during pregnancy in this season? Our information specialists are here to help women and their providers navigate cold and flu season.

Contact Us

Visit Our Exposure Hubs

Exposures may impact your developing baby. Browse our most popular topics on the effects of medications, maternal health, substances, and other exposures. Our Exposure Resource Hubs will help you know if it is a concern for your baby.

Browse topics

Access Our Fact Sheets

Our quick and easy-to-read Fact Sheets answer frequently asked questions about 300+ maternal health conditions, medications, and other exposures during pregnancy and breastfeeding.

Search Now

Discover Our Pregnancy Studies

Our observational studies examine the effects of medications and health conditions during pregnancy. Moms can help improve product safety information and shape the future of healthcare. The information we collect will help women and their healthcare providers make informed treatment decisions during pregnancy. With greater knowledge of the benefits and risks of medications, our community can thrive. Join the movement of moms helping other moms — discover how you can help today!

Learn More

COVID-19 Updates

Our MotherToBaby experts have issued updates to our educational resources on COVID-19 during pregnancy and breastfeeding. Quickly find the essential information that you need.

LEARN MORE

What Can MotherToBaby Offer You?

Resources for Women Who Are Pregnant and/or Breastfeeding

Get easy-to-read information on benefits or risk of medications, drugs, or other exposures during pregnancy and while breastfeeding.

Browse now

Healthcare Professionals

Your one-stop resource for patient education materials, teratogen information services, and research studies for pregnant and lactating patients.

Access materials

Baby Blog News & Updates

Managing Tummy Troubles During Pregnancy

Growing a baby is hard work, and it often comes with a side of extra hunger as your body fuels the little one inside. While the idea of “eating for two” is a common myth, changes in hunger levels, digestion, and food tolerance are very real. For example, you might sit down to enjoy a…

Read Managing Tummy Troubles During Pregnancy

Ep. 91 – From Strep to RHD: A Mother’s Story and a Community’s Fight

Group A strep might sound like a simple sore throat—but for many children and families in American Samoa, it can have life-threatening consequences. In this episode of the MotherToBaby Podcast, we sit down with Dr. Anaise Uso, a public health leader and…

Listen Ep. 91 – From Strep to RHD: A Mother’s Story and a Community’s Fight

Taking Vedolizumab in Pregnancy Did Not Increase the Risk of Birth Defects or Adverse Pregnancy Outcomes

LA JOLLA, CA – Vedolizumab (sold under the trade name Entyvio®) is a medication that is used to treat Crohn’s disease and ulcerative colitis, which are two forms of inflammatory bowel disease (IBD). For women who became pregnant while taking vedolizumab, there…

View Taking Vedolizumab in Pregnancy Did Not Increase the Risk of Birth Defects or Adverse Pregnancy Outcomes

Pregnancy Due Date Calculator

Find out your estimated due date by entering the first day of your last menstrual period and your average cycle length. Did You Know? Only 1 in 20 babies are born on their actual due date. A normal pregnancy often lasts between 38 to 42 weeks, which keeps most parents guessing right up until labor starts!

Request Materials

Order free materials for patients and health providers about our information service and pregnancy studies.

Request

Stay in Touch

Our e-Newsletter brings you the latest information, news, and resources from the experts at MotherToBaby.

Sign Up

Make a Donation

Your generous support helps us provide exposure information to families and health providers.

donate

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2026 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.